Experimental vaccine aims to boost immune attack on colorectal cancer

NCT ID NCT06011772

Ongoing Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding the CIMAvax-EGF vaccine to standard chemotherapy and targeted drugs can trigger an immune response against metastatic colorectal cancer. Only 2 participants with a specific gene type (RAS/BRAF wild-type) were enrolled. The main goal is to see if the vaccine produces enough antibodies, with progression-free survival also tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CIMAvax-EGF vaccine (a vaccine that targets epidermal growth factor)
What this could lead to: If it works, this could point toward a new way to boost the immune system against colorectal cancer when combined with standard treatments.
What could go wrong: This is a very early phase 0 trial with only 2 participants, so results are preliminary and may not apply to others. The vaccine may not trigger a strong enough immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLO-RECTAL CANCER

Contacts and locations

Locations

Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.